GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (BOM:530019) » Definitions » Cyclically Adjusted PS Ratio

Jubilant Pharmova (BOM:530019) Cyclically Adjusted PS Ratio : 1.40 (As of Jun. 16, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Jubilant Pharmova Cyclically Adjusted PS Ratio?

As of today (2024-06-16), Jubilant Pharmova's current share price is ₹754.40. Jubilant Pharmova's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹538.04. Jubilant Pharmova's Cyclically Adjusted PS Ratio for today is 1.40.

The historical rank and industry rank for Jubilant Pharmova's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:530019' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.38   Med: 0.86   Max: 1.84
Current: 1.4

During the past years, Jubilant Pharmova's highest Cyclically Adjusted PS Ratio was 1.84. The lowest was 0.38. And the median was 0.86.

BOM:530019's Cyclically Adjusted PS Ratio is ranked better than
63.84% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.045 vs BOM:530019: 1.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jubilant Pharmova's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹110.623. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹538.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jubilant Pharmova Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Jubilant Pharmova's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova Cyclically Adjusted PS Ratio Chart

Jubilant Pharmova Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 1.34 0.74 0.52 1.06

Jubilant Pharmova Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.74 0.80 1.00 1.06

Competitive Comparison of Jubilant Pharmova's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's Cyclically Adjusted PS Ratio falls into.



Jubilant Pharmova Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Jubilant Pharmova's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=754.40/538.04
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jubilant Pharmova's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Jubilant Pharmova's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=110.623/153.0345*153.0345
=110.623

Current CPI (Mar. 2024) = 153.0345.

Jubilant Pharmova Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 91.695 94.103 149.119
201409 85.539 96.780 135.259
201412 89.711 96.780 141.856
201503 95.586 97.163 150.551
201506 89.467 99.841 137.134
201509 93.049 101.753 139.943
201512 84.940 102.901 126.323
201603 98.441 102.518 146.948
201606 83.395 105.961 120.443
201609 89.658 105.961 129.489
201612 94.572 105.196 137.579
201703 100.437 105.196 146.111
201706 103.925 107.109 148.486
201709 104.025 109.021 146.021
201712 131.014 109.404 183.263
201803 142.728 109.786 198.953
201806 131.367 111.317 180.599
201809 144.077 115.142 191.492
201812 151.015 115.142 200.713
201903 150.776 118.202 195.207
201906 135.116 120.880 171.058
201909 140.440 123.175 174.485
201912 93.869 126.235 113.797
202003 94.008 124.705 115.364
202006 70.297 127.000 84.707
202009 97.264 130.118 114.394
202012 109.480 130.889 128.003
202103 97.443 131.771 113.168
202106 101.393 134.084 115.723
202109 102.591 135.847 115.571
202112 81.434 138.161 90.201
202203 95.199 138.822 104.946
202206 90.528 142.347 97.325
202209 99.777 144.661 105.552
202212 96.316 145.763 101.121
202303 103.858 146.865 108.221
202306 97.906 150.280 99.700
202309 105.069 151.492 106.139
202312 104.698 152.924 104.773
202403 110.623 153.035 110.623

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jubilant Pharmova  (BOM:530019) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Jubilant Pharmova Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jubilant Pharmova (BOM:530019) Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201 301
Jubilant Pharmova Ltd is an integrated global pharmaceutical company. The company's segment includes Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment. Geographically, it derives a majority of its revenue from Americas and Europe.

Jubilant Pharmova (BOM:530019) Headlines

No Headlines